Recent advances in cell-based and cell-free therapeutic approaches for sarcopenia
Sarcopenia is a progressive loss of muscle mass and function that is connected with increased hospital expenditures, falls, fractures, and mortality. Although muscle loss has been related to aging, injury, hormonal imbalances, and diseases such as malignancies, chronic obstructive pulmonary disease, heart failure, and kidney failure, the underlying pathogenic mechanisms of sarcopenia are unclear. Exercise-based interventions and multimodal strategies are currently being considered as potential therapeutic approaches to prevent or treat these diseases. Although drug therapy research is ongoing, no drug has yet been proven to have a substantial safety and clinical value to be the first drug therapy to be licensed for sarcopenia. To better understand the molecular alterations underlying sarcopenia and effective treatments, we review leading research and available findings from the systemic change to the muscle-specific microenvironment. Furthermore, we explore possible mechanisms of sarcopenia and provide new knowledge for the development of novel cell-free and cell-based therapeutics. This review will assist researchers in developing better therapies to improve muscle health in the elderly.
|ISBN||1530-6860 (Electronic) 0892-6638 (Linking)|
|Authors||Wu, S.; Lin, S.; Zhang, X.; Alizada, M.; Wang, L.; Zheng, Y.; Ke, Q.; Xu, J.|
|Publisher Name||FASEB JOURNAL|
|URL link to publisher's version||https://www.ncbi.nlm.nih.gov/pubmed/36250337|